Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 · kind B1 · utility
22Cited by
24References
51Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 10, 1999 |
| Grant date | Apr 15, 2003 |
| Priority date | — |
| Expiry date | Dec 10, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.